Skip to main content
Log in

Chronic myeloproliferative neoplasms

Response to “Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions” by Heidel et al.

  • Correspondence
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Heidel FH, Al-Ali H-K, Hirt C, Kampfe D, Jentsch-Ullrich K, Junghanss C, et al. Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. Leukemia 2018. [Epub ahead of print]

  2. Barbui T, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, et al. Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia. 2018. [Epub ahead of print]

  3. Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016.

    Article  Google Scholar 

  4. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016;353:i2089.

    Article  Google Scholar 

  5. Barosi G, Gale RP Is there expert consensus on expert consensus? Bone Marrow Transplant 2018. [Epub ahead of print]

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Giovanni Barosi.

Ethics declarations

Conflict of interest

GB received advisory board funds from Novartis. FP received advisory board funds from Novartis, Roche and Janssen and speaker bureau funds from Novartis, Sandoz, Janssen and Celgene. PA received a research grant from Sanofi. FP received speaker bureau funds from Novartis. AMV received a fund from Novartis for an advisory board and for research. RPG is a part-time employee of Celgene Corp. TB received advisory board funds from Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barosi, G., Passamonti, F., Accorsi, P. et al. Response to “Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions” by Heidel et al.. Leukemia 32, 2727–2728 (2018). https://doi.org/10.1038/s41375-018-0259-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0259-x

  • Springer Nature Limited

This article is cited by

Navigation